contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


curasight-advances-phase-2-utracer-prostate-cancer-trial

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Philip Coombes

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer.

Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Curasight

This morning, Curasight announced that all nine clinical sites across Germany, Sweden, and Denmark are now recruiting patients in Part 2 of its ongoing Phase 2 uTRACE® trial in prostate cancer, following completion of Part 1 earlier this year. Recruitment is expected to be finalized in H1 2026, marking solid operational progress under the company’s collaboration with Curium Inc., a global leader in nuclear medicine.

This morning, Curasight announced that all nine clinical sites across Germany, Sweden, and Denmark are now recruiting patients in Part 2 of its ongoing Phase 2 uTRACE&#xae; trial in prostate cancer, following completion of Part 1 earlier this year. Recruitment is expected to be finalized in H1 2026, marking solid operational progress under the company&#x2019;s collaboration with Curium Inc., a global leader in nuclear medicine.
The study aims to validate uTRACE&#xae; as a non-invasive imaging tool for improved diagnosis and risk assessment in prostate cancer patients under active surveillance. Under its agreement with Curium, Curasight is eligible for up to USD 70 million in milestone payments and double-digit royalties upon commercialization. Alongside this trial, Curasight also expects to initiate a Phase 1 study of uTREAT&#xae; in brain cancer later this quarter (Q4 2025), advancing its broader theranostic strategy combining diagnostic and therapeutic radiopharmaceuticals.
Disclaimer: HC Andersen Capital receives payment from Curasight for a digitalIR/corporate visibility subscription agreement. / Philip Coombes 08:33 29/10/2025

HC Andersen Capital

<ul><li>Curasight has announced that all nine clinical sites in Germany, Sweden, and Denmark are now recruiting for Part 2 of its Phase 2 uTRACE® trial in prostate cancer, with recruitment expected to complete in H1 2026.</li><li>The trial aims to validate uTRACE® as a non-invasive imaging tool for prostate cancer diagnosis and risk assessment, under a collaboration with Curium Inc., which could yield up to USD 70 million in milestone payments and double-digit royalties for Curasight.</li><li>Curasight plans to initiate a Phase 1 study of uTREAT® in brain cancer in Q4 2025, as part of its strategy to combine diagnostic and therapeutic radiopharmaceuticals.</li><li>HC Andersen Capital receives payment from Curasight for a digitalIR/corporate visibility subscription agreement.</li></ul>This content is generated by AI. You can give feedback on it in the Inderes <a href="https://forum.inderes.com/t/inderes-fi-sisallon-kehitysideat/71/last">forum</a>.

Curasight advances Phase 2 uTRACE® prostate cancer trial

Summary

Login required